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Colorectal cancer (CRC) is one of the most common forms of cancer in western countries and 
represents the second leading cause of cancer mortality in Europe. Early detection and 
removal of cancerous lesions can reduce the incidence of CRC, its mortality and improve 
patients’ quality of life. The main literature on this topic refers to USA and few studies have 
been conducted in Italy to date.  
Aim of the paper is to shed some light on the effectiveness and costs of CRC screening 
programs in the Italian health care system.  
We use as case-study a Regional CRC screening program to determine the full costs and the 
effectiveness of the adopted techniques, FOBT combined with colonoscopy.  
The costs involved in each phase of the program are valued using a micro-costing analysis. 
Effectiveness is valued in terms of early detected lesions and years of life gained. A 
MISCAN-COLON Model© is used to simulate and compare two alternative scenarios, with 
or without the screening program, and estimate the costs for year of life gained. 
The preliminary results show that the screening will prevent almost 1.700 deaths in 30 years 
with an incremental cost effectiveness ratio of € 2.388,63 for life year gained. The results 
outpace those of previous studies, signalling an increasing effectiveness of CRC screening 
programme. Besides, the paper highlights the importance of implementing a screening not 
only for the effects that prevention can have in clinical terms, but also for the economic 
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Colorectal cancer (CRC) is one of the most common forms of cancer in western countries, and 
represents the second leading cause of cancer mortality in Europe (AIRTUM 2009). Early detection 
and removal of cancerous lesions can reduce the incidence of CRC, its mortality (Mandel, Bond et al. 
1993; Selby, Friedman et al. 1993; Lieberman 1995; Mandel, Church et al. 1999; Sonnenberg, Delco 
et al. 2000) and improve patients’ quality of life (Ramsey, Andersen et al. 2000; Ramsey, Berry et al. 
2002; Rauch, Miny et al. 2004; Miles and Wardle 2006; Taupin, Chambers et al. 2006).  
The main literature on this topic refers to USA and few studies have been conducted in Italy so far 
(Lazovich, Weiss et al. 1995; Lieberman 1995; Kronborg, Fenger et al. 1996; Zappa, Castiglione et al. 
1997; Declan Fleming 1998; Tappenden, Chilcott et al. 2007).  
For this reason, the development of a specific study referring to a particular setting has been 
considered appropriate and relevant to shed some light on the effectiveness and the costs of screening 
programs in the Italian framework.  
Aim of the paper is to present the results of a cost-effectiveness analysis of a screening 
program for the colorectal cancer prevention in Italy.  
We use as case-study the experience of a Regional CRC screening program started in 2005 in 
the Province of Ferrara to determine the full cost of the screening program, compare the costs and the 
effectiveness of the adopted techniques (FOBT- faecal occult blood test- and colonoscopy). A micro-
costing analysis is used to identify and evaluate all the costs involved in each phase of the screening 
program considering all the activities carried out during the patient pathway.  
We present the results for the first two years (2005-2007) of screening activity in terms of set 
up costs, development, implementation and management of the prevention program and the costs of 
all the activities of diagnosis (FOBT and colonoscopy), surgery, oncological therapies and follow-up 
of the patients involved in the program. The effectiveness of the screening is valued in terms of early 
detected lesions, avoided deaths and years of life gained. 
The preliminary results show that, after the screening implementation, a huge number of new cases of 
hyperplastic polyps, dysplastic adenomas and carcinomas are detected. Moreover, early diagnosis 
allows the diagnosis of colorectal cancer at the earliest Dukes’ stages (Dukes 1932).  
Finally, we use the cost and effectiveness data collected to estimate the costs for year of life 
gained, using a MISCAN-COLON Model © to simulate and compare two alternative scenarios with 









This study aimed at calculating the cost-effectiveness of the CRC screening. In so doing, two 
separate, but interconnected phases were undertaken. Firstly, the actual cost of the CRC 
screening had to be determined, given that in the Italian context there are not robust proxies 
to estimate the cost of treatments. In so doing, the screening program was analysed in its 
macro-activities: adoption of the Regional project and provincial organization and 
coordination; community communication and information; management of the invitation and 
the FOBT; colonoscopy; surgery; oncology; radio-therapy; and follow-up treatments. In order 
to measure the resource consumption of each activity, a micro-costing methodology was 
adopted. This methodology, although more time-consuming, provides more detailed and 
reliable cost data in comparison to the gross-costing analysis (Brouwer, Rutten et al. 2001; 
Drummond and McGuire 2001). 
The detection and measurement of the cost-item and their value were made through direct 
observation and in collaboration with the hospital and/or local health authority’s staff and 
information system. The only exception was made for the anatomo-pathology laboratory 
costs, given the impossibility to calculate them, the limited relevance to the overall cost of the 
CRC screening and the availability of a Regional tariff system. 
The effectiveness analysis was made adopting a general model for evaluation of the CRC 
screening in the micro-simulation program MISCAN-COLON (Loeve, Boer et al. 1999; 
Loeve, van Ballegooijen et al. 2005). The model is an adapted version of the model MISCAN 
(Habbema, van Oortmarssen et al. 1985), which was originally built and used for the 
evaluation of the breast cancer and cervical cancer. 
The Model is based on a statistical structure as Markov, but it allows a lesser simplification 
and a greater flexibility to explore and analyse the different assumptions. It can be adapted, 
thus, to different type of tests used in performing a screening program.  
Two parts of the program can be distinguished, a natural history part and a screening part. In 
the natural history part of the program, life histories are generated during which colorectal 
polyps and cancer may develop and sometimes cause death and in which no screening takes 
place. In the second part of the program, screening for colorectal cancer is simulated. 
Screening will change some life histories. The aggregated changes in life histories constitute 
the effectiveness of the screening. The effects of different screening policies can be compared 
by applying them to identical life histories. If one is solely interested in modelling the natural 
history of the disease, the screening part is not necessary. The stochastic model underlying 
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the simulation is specified in the input of the program. The input relates to demographic 
characteristics (e.g., the life table), the epidemiology and the natural history of the disease 
(e.g., the duration of preclinical cancer), and the characteristics of screening (e.g., the 
sensitivity of the screening test). 
The total MISCAN-COLON package consists of two programs: (1) the actual simulation 
program, and (2) a post-processing program for processing simulation output. The random 
number generator is divided into two disjoint random number sub-sequences and requires two 
initial seeds. For each source of randomness the number of the random number subsequence 
can be specified, which can be used to reduce variance between simulation runs. For each 
new person in a simulation, the starting points of the random number generators are 
calculated. In this way, as long as the same initial seeds are used in simulations, in every 
simulation the same random number sequence is assigned to a life history. This reduces the 
variance between simulation runs. The output of the actual simulation program consists of 
two files, a file for post-processing and a standard output file. The post-processing file 
contains all important outcomes for the evaluation of a screening policy. It contains results 
per year, useful for detailed analysis, and aggregated totals over time that can be used directly 
by the post-processing program. The output in this file can be subdivided into maximally 
three groups of strata. The preclinical stage assigned to a positive screening or surveillance 
test is defined by the most advanced stage found by the test or during its diagnostic follow-
up. The preclinical stage assigned to a negative test is the most developed stage within reach 
of the screening test. The age groups into which the output is divided, the reference year for 
discounting and the discount rates can be specified. 
For any clinical stage, the annual number of entries and the number life-years can be 
tabulated in the output file on demand. The standard output file contains a summary of the 
input specifications and additional output data if desired, such as incidence and prevalence 
per age group. Extra output can easily be added to both output files. 
The post-processing program uses the discounted totals over time in the post-processing 
output file to calculate the costs and effects of a screening policy. Costs are assigned to 
screening tests, diagnostic tests, surveillance tests, and cancer treatment based on the 
previous described micro-costing analysis. The post-processing program calculates costs per 






3. Results  
In this section we first present the results of the micro-costing analysis for each screening 
phase, then the effectiveness data and, finally, the cost-effectiveness results of the MISCAN 
model simulation.  
 
3.1 Costs results 
In tab.1 we provide a synthesis of the actual costs of each macro-activity of the screening 
program for the biennium 2005-2007.  
The total costs of the first level phase, which includes the set-up, the development, 
implementation and management of the prevention program is some € 393.639,62. 
The unitary cost for a FOBT is € 5,59 per person, for a total cost of  € 271.654,71. Individuals 
with a positive FOBT result are invited for a consultation with a physician, to evaluate the 
possibility to have a second level diagnostic exam. The cost of the visit is almost € 11,00 for 
patient, for a total cost of  almost € 34.081,00  in the biennium. 
For the second level of diagnosis, the cost of each endoscopic exam (partial or complete 
colonoscopy, with or without biopsy and polypectomy) has been calculated separately, in 
order to take into account the different resources consumption in each case (tab. 2).  
The costs for endoscopic exams done in the first wave are almost € 465.000,00 (tab.1). 
In the second level of diagnosis we also included the cost of complications, as blooding or 
perforation that required further interventions such as haemostasis or tattoos.  
The cost of the surgical intervention includes the preparation activities, the operation and the 
post-surgery activities and it takes into account the differences in terms of times and material 
used in each type or intervention (ascendant or descendent colon, transverse colon or sigma).  
On average a single surgical intervention costs between € 2.060,00 and € 2.608,00. 
The cost of the hospitalisation after the intervention has been calculated assuming an average 
length of stay of 7 days and a standard pharmacological therapy.  For each treated patient a 
week of hospitalisation costs on average € 2.097,00. 
For the first two years of screening, the total cost for the surgical treatment of all the 186 
patients, including the costs of hospital in-stay, was almost € 823.000,00 (tab.1). 
After an endoscopic exam or a surgical operation, part of the area detected during the 
investigation is sent to the anatomo-pathologic laboratory for a morphological biopsy.  
The total cost of the anatomo-pathologic exams for the first wave is € 27.000,00 (tab.1). 
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Patients with lesions or cancer are sent to an oncologist to define the most appropriate 
therapy with respect to the cancer localization (colon or rectus), the cancer stage and their 
general health conditions. 
Table 3 provides a summary of the costs of each type of oncological therapy according to the 
cancer stage. The total cost for the oncologic treatment of all the patients with cancer is 
almost € 312.139,00. This includes also the radiotherapy treatments (25 cycles), which costs 
on average € 875,00 per patient (at present, only one patient has been treated with radio-
therapy).  
In rare cases patients require a nutritional therapy of support if they have had an abdominal 
failure at the peritoneum: metastasis can cause an intestinal block and the patient is not able 
to feed anymore. The cost for the treatment of a single patient with an average expected life 
of 3 months is almost € 1.636,70. 
In figure 1 we show the total costs for each macro-activity:  the cost for the first two years of 
screening program is almost € 2.326.000.  
 
 
3.2 Effectiveness results 
The first effectiveness data referred to the screening program have been provided by the 
Tumours Register of the Province. The data show that since 2005, year in which the program 
started, the incidence of all lesions is increased. In particular, hyperplastic polyps are 
increased from 368 new cases in 2005 to 451 in 2006 (versus the 230 of the previous years), 
adenomas are increased from 1.043 new cases in 2005 and 1.242 in 2006 (versus the almost 
800 in the previous years), but especially adenomas with dysplasia are increased from 300 
before the 2005 to 444 and 655 in 2005 and 2006 respectively. Finally, in 2006 have been 
detected 492 new cases of cancer versus the 455 new cases in 2005.  
An important result of the screening program concerns the stage of the detected tumours: 
since 2005 the cases of cancer in Dukes’stage A are increased from 10% to 14% with respect 
to 2004, whereas the cases of cancer in the worst stages are decreased, from 9,4% to 8,1% in 
stage B, from 53,2% to 50,6% in stage C and form 17,1% to 16,5% in stage D.   
In the biennium 2005-2007 the incidence was of 12,6% for polyps, 47,6% for adenomas, 29% 
for dysplastic adenomas and 10,8% for cancers.  Comparing these data with the incidence 
percentage registered before the screening program implementation (13,1% of polyps, 46% 
of adenomas, 18,2% of dysplastic adenomas and 22% of cancers) we can see how an early 
diagnosis of dysplastic adenomas can reduce the incidence of colorectal cancer in the future.  
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Adenomas, if early detected and removed can increase the possibility of a total eradication 
without metastasis diffusion (Mandel, Bond et al. 1993; Winawer, Zauber et al. 1993). This 
confirms the importance of the screening program, which not only can reduce the incidence 
of cancer and save human lives, but also can save future costs due to avoided surgical and 
oncologic treatments for the most advanced disease stages.  
 
 
3.3 Cost-effectiveness results - MISCAN model simulation  
The simulation program provides two outputs: a file containing all the outcomes for the 
evaluation of the screening policy (post-proceeding file) and a standard output file.  
Results are reported per year and aggregated over time.  
The file specifies the age groups into which the output is divided, the reference year for 
discounting and the discount rates. The annual number of entries and the number life-years 
are reported for each clinical stage. The discounted totals over time contained in the post-
processing output file are used to calculate the costs and effects of the screening program.  
Predicted effects and costs are calculated assuming a population of one million individuals, 
for a whole period of 30 years and in the two different scenarios, the one presence of biennial 
FOBT screening, and the one without screening. Effects and costs are discounted according 
to three discount rates: 1.5%, 3% and 4%1. 
In table 4 we report the predicted effects in terms of number of deaths and years of life lost 
for CRC. The results show that the screening allows a reduction of more than 1.770 deaths 
from CRC and a reduction of almost 17.000 life years lost (at 3% discount rate). 
Costs are assigned to screening tests, diagnostic tests, cancer treatment and follow-up. The 
incremental costs of the screening program compared to the situation in absence of screening 
are almost € 40.983.000 (at 3% discount rate) as reported in table 5.  
The cost effectiveness of the screening program is given by the ratio between the total 
screening costs and the prevented deaths or life-years gained. 
The incremental cost effectiveness ratio (ICER) of the screening program compared to the 
situation in absence of screening is given by the ratio between the incremental costs of the 










                                                 
1 We use a 3% discount rate according to the NICE guidelines. 
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 The final results (tab. 6) show that the ICER (Incremental Cost Effectiveness Ratio) of the 
program, compared with no screening, for a 3% discount rate, is € 2.388,63 for life year 





The results presented in this work show that a colorectal cancer screening program has 
certainly a great impact in terms of costs borne by the local health organization and the 
society. In presence of screening new cases of lesions and cancers can be detected, increasing 
the cost for the following treatments that would not have been borne in absence of screening. 
Nevertheless the effectiveness of the screening program cannot be valued only in clinical 
terms (number of lesions diagnosed, number of lives saved) but also in economic terms: the 
screening allows an early detection of adenomas and lesions at the first stages, with 
consequent savings of money due to avoided future treatments.   
From an economic point of view, also the compliance rate has a strong impact in the program 
effects, as the fixed costs born to adopt and implement the program can be highly spread, 
reducing the unitary cost of the screening for single patient. A high compliance can increase 
the costs due to further diagnostic exams and treatments for the people found positives, but 
can also avoid the future costs of treatments, especially for the latest and worst stages of the 
disease.  
The preliminary results of the MISCAN-COLON Model simulation show that the screening 
program will prevent almost 1.700 deaths, with 17.158 years of life gained in a period of time 
of 30 years (at a discount rate of 3%). Comparing the costs borne in the first wave of the 
screening with the number of years potentially saved, the model show that the incremental 
cost effectiveness ratio of the program is almost € 2.388,63 for life year gained.  
The results of this study confirm the results of similar studies conducted in other countries 
(Sonnenberg, Delco et al. 2000; Sonnenberg and Delco 2002) and highlight the importance of 
implementing a screening program not only for the importance that prevention can have in 
clinical terms, but also for the economic impact of such a policy to save future avoidable 
expenses.  
The different results obtained in our analysis, compared to Sonnenberg’s, can be explained by 
four main factors. First of all, the rate of participation of the target population to the screening 
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is one of the factors that can impact on the effectiveness of any prevention program. 
Secondly, the epidemiologic characteristics of the target population that has above the 
average rates of CCR prevalence and mortality. Thirdly, the medical advancement in the 
treatment of cancer may have increased also the cost of therapy given the time lag between 
the Sonnenberg’s study and our own. Finally, we adopted a micro-costing analysis that 
provided the study with more reliable data, than proxies like DRGs. However, these 
preliminary considerations needs to be further studied through technique such as the 
sensitivity analysis. 
Some limitations of the study need to be considered. From a wider societal and economic 
perspective, we neglected the indirect costs of the screening program, such as the time off 
work for the subjects and their caregivers, travel costs, production losses, out of pocket 
expenses and intangible costs (Heitman, Au et al. 2008). 
Besides, we did not considered any measure for the psychosocial consequences of the 
screening in terms of quality of life for the patients (Whynes, Neilson et al. 1994; Brodersen, 
McKenna et al. 2007) and mental health (Taupin, Chambers et al. 2006). Participation in 
screening programs for malignant disease may have psychological health effects that could 
outweigh the beneficial effects of the screening itself (Wardle, Williamson et al. 2003; 
Wardle, Williamson et al. 2003) and increase the anxiety in case of positive results (Miles 
and Wardle 2006). Attendance to screening program may results from individual risk 
aversion, patients’preferences (Pignone, Bucholtz et al. 1999) and psychosocial impacts 
(Tymstra and Bieleman 1987; Ling, Moskowitz et al. 2001). 
Italy, as other countries world-wide, is going towards a national screening program, giving 
autonomy to the Regions to organise and manage the activities. In many Regions, like in the 
Emilia-Romagna, we have a large-scale data base with results from a real-world setting. 
Despite the limitations, the results strongly suggest that the screening program, through 
FOBT test, is likely to be cost-effective in the long-run. These data represent a relevant and 
strong argument to continue with, in the specific case of the Emilia-Romagna Region, and 








Tab. 1 Cost for each activity, volumes and unitary cost for patient 
Activity  Total Cost  Overall activity Unitary costs* 
Adoption and coordination  €    122.729,30   99.207   invited  €             2,53 
Information activity  €      38.362,20   99.207   invited  €             0,79 
Management  €    232.548,12   99.207   invited  €             4,79 
FOBT   €    271.654,71       48.596  tests   €            5,59  
Second Level-Colonoscopy   €    498.724,41         2.362  exams   €        211,14  
Surgery  €    823.127,52            186 patients  €     4.425,42  
Anatomo pathology  €      26.787,61        
Chemo-radio therapy  €    312.138,94            198 patients  €     1.576,46  
*the unitary cost has been calculated over the total number of patients entering the screening 
  Source: our elaboration 
 
Tab. 2 Cost for each type of endoscopic examination 
Endoscopic examination Unitary cost 
Complete colonoscopy (explorative) € 171,00 
Complete colonoscopy with biopsy  € 179,53 
Complete colonoscopy with polypectomy  € 232,10 
Partial colonoscopy (explorative) € 140,54 
Partial colonoscopy with biopsy  € 171,64 
Partial colonoscopy with polypectomy € 149,07 
Source: our elaboration 
Tab. 3 Costs of oncological therapies for each Dukes’ stage of CRC 
Colon treatments Nr. of patients Cost per patient* Total costs 
Polyps  €        23,62  
A and B not at risk 112 €        23,62 €  2.644,97 
B at risk and C, without comorbidities    
Folfox (6 cycles) 33 €    4.496,42 €  148.381,87 
B at risk and C, with comorbidities     
Capecitabine (8 cycles) 42 €    3.383,16 €  142.092,84 
D I line    
Folfiri+Bevaciz. (3 months) 6 €    2.882,81 €  17.296,83 
D II line    
Folfiri+Cetuximab (3 months)  €  11.082,03  
CPT-CET (3 months)  €  13.949,69  
Folfox (3 months)  €    4.496,42  
D III line    
Fumit-Mitomicina (3 months)  €       772,95  
D with comorbidities    
Capox (3 months)  €    5.023,81  
Fufaset (3 months)  €       863,92  
Rectum treatments  Nr .of patients Cost per patient* Total costs 
A and B not at risk 4 €        23,62 €   94,46 
not surgically treateed, without comorbidities    
Fluoruroracil + RT (35 days) 1 €       752,84 € 752,84  
not surgically operated,  




Capecitabine + RT (5 weeks)  €       864,46  
B surgically treated    
DeGramont+5FU+RT+DeGramont    
C stage    
       Folfox+FU-IC+RT+Folfox  €    4.496,42  
Radiotherapy (25 cycles) 1 €       875,00 €       875,00 
 
*The unitary cost has been calculated assuming a patient with an average body mass of 70 kilos of 
weight and 170 cm of height. 
Source: our elaboration 
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Tab. 4 Predicted discounted effects of the screening compared to the situation in absence of 
screening 
 
Number of patients invited and screened    
Discount rate 0.03     
  screening no screening difference 
Nr. First Invited 450.297 0 450.297 
Nr. rep inv. 2.033.153 0 2.033.153 
Tot. invited 2.483.450 0 2.483.450 
Nr. first screened 225.235 0 225.235 
Nr. repeated s creen. 894.035 0 894.035 
Nr. positives  54.366 0 54.366 
Nr. negatives 1.064.904 0 1.064.904 
Total screenings 1.119.270 0 1.119.270 
Tot. Tests surv. 124.714 0 124.714 
        
Effects       
Discount rate 0.03     
  screening no screening difference 
Death for disease 14.137 15.913 -1.776 
Life Years lost for  CRC 173.830 190.988 -17,158 
Source: our elaboration of MISCAN simulation results 
 
 
Tab. 5 Predicted discounted costs of the screening compared to the situation in absence of 
screening  
 
Costs       
Discount rate 0.03   
  screening no screening difference 
Screenings 15.620.900 0 15.620.900 
Surveillance tests 28.582.958 0 28.582.958 
Diagnost. screening 11.442.978 0 11.442.978 
Clinic. Diagnost. 8.002.901 9.437.482 -1.434.581 
Screen Complications 0 0 0 
Surv. Complications  374,142 0 374.142 
Compl. diag. in scr. pr 124,749 0 124.749 
Compl.  clin. diag. 77,198 91,037 -13.838 
Total treatment 213.193.340 226.907.420 -13.714.080 
Total costs 277.419.166 236.435.938 40.983.228 




Tab. 6 Incremental cost-effectiveness ratio of CRC screening program 
Discount factor 0.00 0.03 0.015 
Incremental Costs       
Screening costs  €    23.375.393   €    15.620.899   €       18.923.186  
Surveill. costs   €    63.272.752   €    28.582.957  €       41.689.740  
Diagnostic costs   €    16.817.046  €    11.442.978   €       13.734.907 
Clinic diagnostic costs -€      2.980.002  -€      1.434. 580  -€         2.022.712  
Complic costs  €         988.443   €         485.052  €           677.713  
Treatment costs -€    38.660.000 -€    13.714.080  -€       22.878.570 
Total costs  €    62.813.632   €    40.983.227   €       50.124.264 
Effectiveness       
Lives gained 4.214 1.776 2.674 
Life years gained 46.863 17.158 27.746 
Incremental Cost-
Effectiveness ratio       
Cost per avoided death    €           14.905  €           23.082  €             18.742  
Cost per life year   €            1.340  €            2.388  €               1.806  
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